Reviewed by Danielle Ellis, B.Sc.Nov 7 2023 In a peer-reviewed study published today in Nature Communications, a team of scientists from French-American techbio Owkin and pathology labs in France present a blind validation of MSIntuit™ CRC, a first-in-class AI-driven digital pathology diagnostic developed by Owkin, as a pre-screening tool aimed at optimizing the precision of diagnosis and treatment of colorectal cancer.
Microsatellite Instability is a key genomic biomarker in colorectal cancer and represents ~15% of the overall CRC population. Recent clinical trials have shown that MSI phenotype has both prognostic and therapeutic importance, especially with the recent approval of immune checkpoint inhibitor therapies. Those patients whose tumors show MSI, are considered likely to respond to ICI therapy and recommended for it.
Today's study published in Nature Communications reveals that MSIntuit CRC can accurately rule out nearly 50% of MSS patients, while correctly classifying more than 96% of MSI patients, on par with current gold standard methods . Such new solutions pave the way for an optimized screening workflow to screen more patients, faster.
"Our solution represents the first step towards the development of an AI diagnostic that can identify actionable biomarkers from a single H&E slide used in clinical routine, pushing us closer to realizing a precision medicine future."
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: medical_xpress - 🏆 101. / 51 Read more »